Latest Pacira Pharmaceuticals (PCRX) Headlines
Post# of 46
Posted On: 03/13/2014 1:00:02 AM
Latest Pacira Pharmaceuticals (PCRX) Headlines
Pacira Pharmaceuticals names Dr Yvonne Greenstreet to board
M2 - Fri Mar 07, 6:12AM CST
Pharmaceutical company Pacira Pharmaceuticals (NasdaqGS
CRX) revealed on Thursday the addition of Dr Yvonne Greenstreet, MBChB, MBA, to its board of directors.
Pacira Pharmaceuticals Inc. Appoints Industry Expert Yvonne Greenstreet to its Board of Directors
Business Wire - Thu Mar 06, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ CRX) today announced the appointment of Yvonne Greenstreet, MBChB, MBA, to its board of directors.
Stock Price Movements, Official Platinum Sponsor Status, Conference Schedules, Appointments and Clinical Trial Results - Analyst Notes on Intuitive, Agilent, Teleflex, WuXi PharmaTech, and Pacira
PR Newswire - Wed Mar 05, 3:00PM CST
Editor Note: For more information about this release, please scroll to bottom.
Pacira Pharmaceuticals Announces EXPAREL(R) Data Presentations at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons
Business Wire - Wed Mar 05, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that data evaluating the use of EXPAREL(R) (bupivacaine liposome injectable suspension) to manage postsurgical pain following knee and hip arthroplasty (replacement) procedures will be presented at the 81st annual meeting of the American Academy of Orthopedic Surgeons (AAOS). The meeting will be held on March 11-15, 2014 at the Ernest N. Morial Convention Center in New Orleans. EXPAREL is indicated for single-dose administration into the surgical site to produce postsurgical analgesia.
This Week in Biotech: 2 FDA Approvals and 3 Clinically Impressive Studies
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 2:15PM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Pacira Pharmaceuticals, Inc. Announces EXPAREL Phase 3 Clinical Trial in Femoral Nerve Block Meets Primary Efficacy Endpoint
Business Wire - Thu Feb 27, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ CRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL(R) (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint.
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
Business Wire - Wed Feb 26, 4:34PM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference on Thursday, March 13, 2014, at 9 a.m. ET in Miami. Mr. Stack is expected to present an overview of the company.
Wider-than-Expected Loss at Pacira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 11:20AM CST
Pacira Pharmac reported fourth quarter 2013 net loss per share of 36 cents, wider than the Zacks Consensus Estimate of a loss of 31 cents
Pacira Pharmaceuticals, Inc. Webcast Replay of 2013 Financial Results Conference Call
GlobeNewswire - Tue Feb 25, 2:36PM CST
Pacira Pharmaceuticals, Inc. (Nasdaq CRX) today announced that a replay of the company's fourth quarter and full-year 2013 financial results conference call, which took place today on Tuesday, February 25, 2014, at 9 a.m. ET, can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international), and providing the Conference ID 16366107. The replay of the call will be available for two weeks from the date of the live call.
Pacira Pharmaceuticals, Inc. Reports 2013 Financial Results: Fourth Quarter EXPAREL Revenues Increase 53 Percent Over Third Quarter
Business Wire - Tue Feb 25, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ CRX) today provided updates on the commercial success of EXPAREL(R) (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the fourth quarter and full year ended December 31, 2013.
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 13, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Pacira Pharmaceuticals, Inc. Announces Timing for 2013 Financial Results Webcast and Conference Call
Business Wire - Tue Feb 11, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ CRX) today announced that financial results for the company's fourth quarter and year ended December 31, 2013, will be released before the market opens on Tuesday, February 25, 2014. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Tuesday, February 25, 2014, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) fifteen minutes prior to the start of the call.
Update on Pacira's Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 4:50PM CST
Pacira released data supporting the use of Exparel infiltrated into the iTAP for postsurgical pain management
Data Update Supports Infiltration with EXPAREL(R) into the Transversus Abdominis Plane for Postsurgical Pain Management
Business Wire - Wed Jan 29, 3:30PM CST
Pacira Pharmaceuticals, Inc. (NASDAQ CRX) today announced key findings supporting the use of EXPAREL(R) (bupivacaine liposome injectable suspension) infiltrated into the transversus abdominis plane (or iTAP) for postsurgical pain management.
Is Pacira Pharmaceuticals (PCRX) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 17, 7:50AM CST
Pacira Pharmaceuticals is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
Hemostasis Global Clinical Trials Review, H2, 2013
M2 - Thu Jan 16, 9:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9kt67/hemostasis_global) has announced the addition of the "Hemostasis Global Clinical Trials Review, H2, 2013" report to their offering. Hemostasis Global Clinical Trials Review, H2, 2013 provides data on the Hemostasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemostasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hemostasis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Hemostasis Therapeutics Clinical Trials - Baxter International Inc. - Johnson & Johnson - Novo A/S - ZymoGenetics, Inc. (Inactive) - Takeda Pharmaceutical Company Limited - Teva Women's Health - ProFibrix, BV. - Grifols, S.A. - Ethicon, Inc. - B. Braun Melsungen AG Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - National Taiwan University Hospital - Cardiovascular Institute & Fuwai Hospital - University of Manitoba - Medical University of Silesia - Esbjerg Dentallaboratorium Aps - Karolinska Institutet - The University of Hong Kong - Chinese University of Hong Kong - University Hospital Basel For more information visit http://www.researchandmarkets.com/research/b9...sis_global
Healthcare Companies Report Stock Price Movement, Conference Call Schedules, Study Results, and Presentations - Research Report on Merck, Keryx Biopharma, Pacira, Ligand Pharma, and Dyax
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), and Dyax Corp. (NASDAQ: DYAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
New Data on Pacira's Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 08, 5:11PM CST
Pacira Pharma reported results from the IMPROVE study on Exparel which was published in the journal Current Therapeutic Research
Phase 4 IMPROVE Publication Finds EXPAREL(R)- Based Multimodal Analgesia Reduces Opioid Use, Adverse Events and Hospital Stay Following Laparoscopic Surgery
Business Wire - Tue Jan 07, 3:29PM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from the IMPROVE study in laparoscopic colectomy. IMPROVE represents a series of open-label prospective Phase 4 clinical studies to assess the differences in postsurgical opioid use and health economic outcomes between patients receiving EXPAREL(R) (bupivacaine liposome injectable suspension) as the foundation of a multimodal analgesic regimen versus a standard opioid-based regimen for postsurgical pain control. The results were published in the January issue of Current Therapeutic Research.
Pacira Pharmaceuticals names Dr Yvonne Greenstreet to board
M2 - Fri Mar 07, 6:12AM CST
Pharmaceutical company Pacira Pharmaceuticals (NasdaqGS
CRX) revealed on Thursday the addition of Dr Yvonne Greenstreet, MBChB, MBA, to its board of directors. Pacira Pharmaceuticals Inc. Appoints Industry Expert Yvonne Greenstreet to its Board of Directors
Business Wire - Thu Mar 06, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ
CRX) today announced the appointment of Yvonne Greenstreet, MBChB, MBA, to its board of directors. Stock Price Movements, Official Platinum Sponsor Status, Conference Schedules, Appointments and Clinical Trial Results - Analyst Notes on Intuitive, Agilent, Teleflex, WuXi PharmaTech, and Pacira
PR Newswire - Wed Mar 05, 3:00PM CST
Editor Note: For more information about this release, please scroll to bottom.
Pacira Pharmaceuticals Announces EXPAREL(R) Data Presentations at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons
Business Wire - Wed Mar 05, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that data evaluating the use of EXPAREL(R) (bupivacaine liposome injectable suspension) to manage postsurgical pain following knee and hip arthroplasty (replacement) procedures will be presented at the 81st annual meeting of the American Academy of Orthopedic Surgeons (AAOS). The meeting will be held on March 11-15, 2014 at the Ernest N. Morial Convention Center in New Orleans. EXPAREL is indicated for single-dose administration into the surgical site to produce postsurgical analgesia.
This Week in Biotech: 2 FDA Approvals and 3 Clinically Impressive Studies
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 2:15PM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Pacira Pharmaceuticals, Inc. Announces EXPAREL Phase 3 Clinical Trial in Femoral Nerve Block Meets Primary Efficacy Endpoint
Business Wire - Thu Feb 27, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ
CRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL(R) (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint. Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
Business Wire - Wed Feb 26, 4:34PM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference on Thursday, March 13, 2014, at 9 a.m. ET in Miami. Mr. Stack is expected to present an overview of the company.
Wider-than-Expected Loss at Pacira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 11:20AM CST
Pacira Pharmac reported fourth quarter 2013 net loss per share of 36 cents, wider than the Zacks Consensus Estimate of a loss of 31 cents
Pacira Pharmaceuticals, Inc. Webcast Replay of 2013 Financial Results Conference Call
GlobeNewswire - Tue Feb 25, 2:36PM CST
Pacira Pharmaceuticals, Inc. (Nasdaq
CRX) today announced that a replay of the company's fourth quarter and full-year 2013 financial results conference call, which took place today on Tuesday, February 25, 2014, at 9 a.m. ET, can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international), and providing the Conference ID 16366107. The replay of the call will be available for two weeks from the date of the live call. Pacira Pharmaceuticals, Inc. Reports 2013 Financial Results: Fourth Quarter EXPAREL Revenues Increase 53 Percent Over Third Quarter
Business Wire - Tue Feb 25, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ
CRX) today provided updates on the commercial success of EXPAREL(R) (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the fourth quarter and full year ended December 31, 2013. Nasdaq stocks posting largest percentage increases
AP - Thu Feb 13, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Pacira Pharmaceuticals, Inc. Announces Timing for 2013 Financial Results Webcast and Conference Call
Business Wire - Tue Feb 11, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ
CRX) today announced that financial results for the company's fourth quarter and year ended December 31, 2013, will be released before the market opens on Tuesday, February 25, 2014. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Tuesday, February 25, 2014, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) fifteen minutes prior to the start of the call. Update on Pacira's Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 4:50PM CST
Pacira released data supporting the use of Exparel infiltrated into the iTAP for postsurgical pain management
Data Update Supports Infiltration with EXPAREL(R) into the Transversus Abdominis Plane for Postsurgical Pain Management
Business Wire - Wed Jan 29, 3:30PM CST
Pacira Pharmaceuticals, Inc. (NASDAQ
CRX) today announced key findings supporting the use of EXPAREL(R) (bupivacaine liposome injectable suspension) infiltrated into the transversus abdominis plane (or iTAP) for postsurgical pain management. Is Pacira Pharmaceuticals (PCRX) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 17, 7:50AM CST
Pacira Pharmaceuticals is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
Hemostasis Global Clinical Trials Review, H2, 2013
M2 - Thu Jan 16, 9:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9kt67/hemostasis_global) has announced the addition of the "Hemostasis Global Clinical Trials Review, H2, 2013" report to their offering. Hemostasis Global Clinical Trials Review, H2, 2013 provides data on the Hemostasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemostasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hemostasis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Hemostasis Therapeutics Clinical Trials - Baxter International Inc. - Johnson & Johnson - Novo A/S - ZymoGenetics, Inc. (Inactive) - Takeda Pharmaceutical Company Limited - Teva Women's Health - ProFibrix, BV. - Grifols, S.A. - Ethicon, Inc. - B. Braun Melsungen AG Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - National Taiwan University Hospital - Cardiovascular Institute & Fuwai Hospital - University of Manitoba - Medical University of Silesia - Esbjerg Dentallaboratorium Aps - Karolinska Institutet - The University of Hong Kong - Chinese University of Hong Kong - University Hospital Basel For more information visit http://www.researchandmarkets.com/research/b9...sis_global
Healthcare Companies Report Stock Price Movement, Conference Call Schedules, Study Results, and Presentations - Research Report on Merck, Keryx Biopharma, Pacira, Ligand Pharma, and Dyax
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), and Dyax Corp. (NASDAQ: DYAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
New Data on Pacira's Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 08, 5:11PM CST
Pacira Pharma reported results from the IMPROVE study on Exparel which was published in the journal Current Therapeutic Research
Phase 4 IMPROVE Publication Finds EXPAREL(R)- Based Multimodal Analgesia Reduces Opioid Use, Adverse Events and Hospital Stay Following Laparoscopic Surgery
Business Wire - Tue Jan 07, 3:29PM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from the IMPROVE study in laparoscopic colectomy. IMPROVE represents a series of open-label prospective Phase 4 clinical studies to assess the differences in postsurgical opioid use and health economic outcomes between patients receiving EXPAREL(R) (bupivacaine liposome injectable suspension) as the foundation of a multimodal analgesic regimen versus a standard opioid-based regimen for postsurgical pain control. The results were published in the January issue of Current Therapeutic Research.
(0)
(0)Pacira Pharmaceuticals Inc. (PCRX) Stock Research Links
Scroll down for more posts ▼